Navigation Links
Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, announced results from two pre-clinical studies that support the role of SPARC (secreted protein acidic and rich in cysteine) expression in cancer and Abraxis' nanoparticle albumin-bound (nab(TM)) tumor-targeting technology at the 98th American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2007 in Los Angeles.

"Both pre-clinical studies evaluating the role of SPARC expression provide strong evidence in support of the mechanism of action for our nab-technology therapeutic candidates," said Neil P. Desai, Ph.D., vice president of research and development at Abraxis BioScience. "By leveraging the natural properties of albumin, nab-technology allows for the transport and delivery of higher concentrations of anticancer agent directly to the tumor without the use of toxic solvents. Both pre-clinical and clinical studies have shown that this may lead to an increase in the drug's antitumor effect without increasing side effects."

The first of two pre-clinical studies demonstrated that SPARC is an albumin-binding protein and that the level of the SPARC expression could be correlated with the response of tumors to nab-paclitaxel. This provides concrete support for the earlier hypothesis that higher levels of SPARC protein may lead to enhanced antitumor effect of nab-paclitaxel, which is marketed in the United States under the brand name ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particle for injection (albumin bound). (Abstract #3480; SPARC Overexpression Enhances Sensitivity to nab-paclitaxel In Vivo).

The second of the two pre-clinical studies identified a novel spliced variant of SPARC gene that differed from known human SPARC mRNA sequence by a single amino acid residue. Although the role of this form of SPARC is still under
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:5/16/2008)...ss., May 16 /- BioVex Inc, a biotechn...n oncology and infectious,disease, announced today...from its Phase II clinical trial of OncoVEX GM-CSF...at the American Society of Clinical Oncology,(ASCO...ary of the abstract,which describes the data as of...
(Date:5/16/2008)... as Potential Biomarkers -- for Lung Cancer Diagno...s With Cancer of Unknown Primary ...tify Cancer Types With High Sensitivity and, Spe...atment of Cancer Results of microRNA Signature to...curacy Exceeding 90% and Specificity of 99%, REHO...
(Date:5/16/2008)...monstrates Statistically Significant Reductions in...ions, - Abstract to be published in 2008 Proceedin... Clinical Oncology, SAN DIEGO, May 16 /PRNew... (Amex: ANX ) announced today that, in a registra...nstrated a statistically significant reduction,in ...
(Date:5/15/2008)...tzerland, May 15 /- Patients with bre...common cancers, can expect,further treatment advan...,(trastuzumab) following new data that is being pr...ncology (ASCO) annual meeting in Chicago at,the en...d the meeting which,is the premier event for cance...
Breaking Medicine Technology:BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Dis 13107 1Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Dis 13107 2Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Dis 13107 3Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Dis 13107 4Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Dis 13107 5Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Dis 13107 6Jiffy Lube 28R 29 Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 13104 1Jiffy Lube 28R 29 Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 13104 2Jiffy Lube 28R 29 Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 13104 3Jiffy Lube 28R 29 Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 13104 4Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 1Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 2Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 3Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 4NutriSystem and Celebrities Team Up to Benefit the American Heart Association 13102 1NutriSystem and Celebrities Team Up to Benefit the American Heart Association 13102 2NutriSystem and Celebrities Team Up to Benefit the American Heart Association 13102 3
...ustralia, April 26, 2007 /PRNewswire-FirstCall/ --...ted today,announced preliminary results from its r... metastatic colorectal cancer, where,Alchemia,s dr...considered to be a cornerstone drug for the treatm...ng made at a preliminary stage of,the analysis in ...
...dent Japanese study demonstrates dramatic,benefits...udy halted early due to superior outcomes for,Diov... 2007 - New findings from the independent,Jikei H... that,adding the blood pressure lowering medicatio...ramatic 39% reduction in,cardiovascular events and...
Other Medicine Technology:Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 2Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 3Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 4Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 5Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 6Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 7Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
(Date:5/16/2008)... BEACH, Fla., May 16 /PRNewswire-USNewswire/- "Huh...ften by Americans, particularly our,children. More...uals, have,significant hearing loss and the number...every 100 school age children have some form of he...his social and economic problem,is what led Kathly...
(Date:5/16/2008)...ebecca Haag,s Statement for National HIV Vaccine A...ire-USNewswire/ -- Twenty-six years into the,AIDS ... 13 minutes in the,U.S. On Sunday, May 18, HIV Vac...nal partners in the National Institute of Allergy ...h Education Initiative, urges everyone,to help end...
(Date:5/16/2008)...INGTON, May 16 /PRNewswire-USNewswire/ -- As tropi... the Irrawaddy delta, survivors of,Cyclone Nargis ...ms. Many,survivors still need assistance, as expos...ing an increasingly dire situation., "The people ... to,recover from this disaster and get back on the...
(Date:5/16/2008)...O, Fla., May 16 /PRNewswire/ -- ExamForce announce...rporate and Government Sales Manager.,Mongeon form...r (ISC)2,Americas where he oversaw government sale...al, one of the top security certifications in the ...Florida, recently left (ISC)2,Americas to spend mo...
Breaking Medicine News(10 mins):Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Myanmar Cyclone Survivors Face New Challenges 2
...e of an operation forcing doctors to operated usin...e Vietnamese hospital// were trying to deliver a c...y one of the doctors on Thursday. The surgeons w...ction operation on a mother. It was at this point ...
...d team from Virginia Polytechnic Institute and Sta...clines// significantly in men after one year of co...es the removal of blocks in more than one coronary...provide oxygen rich blood to the rest of the body....
...ottest month in the last 100 years. There has bee...roorganism cryptosporidium, in this part of the co...asitic outbreak compare with just 52 , for the sam...ble Disease Control Branch director Ann Koehler de...
...tes say researchers. If you are a woman, it can si... // Researchers from the Department of Surgical a...al in Sweden, led by Dr. Par Stattin conducted a s...anning a period of 13 years. The participants were...
Other Medicine News:Health News:Women – watch Your Fat and Sugar Intakes to Keep Cancer at Ba 2
Completely revised and updated for 2005, this practical handbook is an up-to-date guide to all aspects of cancer chemotherapy. The book provides a comprehensive, easy to use catalog of over 100 drugs
A handy quick-reference tool for busy residents and clinicians with key facts and points essential for day-to-day patient care.
...s and health consumers from the trusted American S...eatured in MedMaster includes why the medication i...e effects and warning signs of adverse drug reacti... information on what to do if a dose is missed, an...
The mission of AHFS DI Essentials (American Hospital Formulary Service) is to provide an evidence-based foundation for safe and effective drug therapy.
Medicine Products: